Aktie A2AF74 HUTCHMED (CHINA) LIMITED
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen HUTCHMED (China) Limited Nasdaq

Aktien

A2AF74

US44842L1035

HCM

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:00:00 17.05.2024 		% 5 Tage % 1. Jan.
20,17 USD -3,77 % Intraday Chart für HUTCHMED (China) Limited -7,26 % +11,37 %
17.05. Hutchmed China Simon To verlässt seinen Posten, Nachfolger ist Dan Eldar AN
17.05. Hutchmed kündigt Rücktritt von Simon To als Chairman an und benennt Dan Eldar als Nachfolger MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Hutchmed China Simon To leaves role, succeeded by Dan Eldar
Hutchmed Announces Retirement of Simon To as Chairman, Names Dan Eldar Successor
HUTCHMED Limited Announces Executive Changes
Hutchmed (China) to Present Sovleplenib Phase III Data at EHA2024 Congress
HUTCHMED Limited Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to Be Presented at the Upcoming EHA2024 Congress
Hutchmed announces trials of HMPL-306 and Surufatinib cancer therapies
Hutchmed Starts Phase 2/3 Trial of Surufatinib Combination Therapy in Pancreatic Cancer
HUTCHMED Limited Initiates the RAPMichael Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
Hutchmed Starts Phase 2/3 Trials for Pancreatic Cancer Drug in China; Shares Rise 3%
Hutchmed Begins Phase 3 Trials for Leukemia Medication in China
HUTCHMED Limited Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naive Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui
HUTCHMED Limited Appoints Dr. Renu Bhatia as an Independent Non-Executive Director and a Member of Technical Committee, Effective May 13, 2024
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug
Hutchmed notes CHMP's positive opinion for fruiquintinib approval
European Medicines Agency Committee Backs Approval of Takeda's Fruquintinib to Treat Colorectal Cancer
Hutchmed to Present New Data at US Cancer Research Conference
HUTCHMED Limited Highlights Data to be Presented at AACR Congress 2024
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status
Hutchmed endometrial cancer treatment application accepted for review
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2PJ5B Aktie
  4. A2AF74 Aktie
  5. Nachrichten HUTCHMED (China) Limited
  6. Andere Sprachen